Compounds specific to adenosine A, receptors and uses thereof
AssigneeOSI Pharmaceuticals, Inc.
InventorsArlindo L. Castelhano, Bryan McKibben, David J. Witter
Life of this patent
Estimating the term…
Abstract
This invention pertains to compounds which specifically inhibit the adenosine A1 receptor and the use of these compounds to treat a disease associated with A1 adenosine receptors in a subject.
Claims60
A compound having the structure:
- 287
- wherein
- R1NR2 together form a ring having the structure:
- 288
- or R1 is H and R2 is:
- 289
- R5 is H, or substituted or unsubstituted alkyl or alkylaryl.
A method for treating a subject afflicted with a disease associated with an A1 adenosine receptor in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound having the structure:
- 306
- or a pharmaceutically acceptable salt thereof so as to thereby treat the subject, wherein the disease is antidiuresis, bradycardia, bronchitis, bronchoconstriction, Alzheimer's disease, cardiac arrythmias, cardiac hypoxia, congestive heart failure, hypertension, inflammation, negative cardiac inotropy and dromotropy, renal failure, sedation or is associated with transmitter release, respiratory epithelia, contraction of smooth muscle underlying respiratory epithelia, vasoconstriction or mast cell degranulation.
A method for inhibiting the activity of an A1 adenosine receptor in a cell, which comprises contacting the cell with a compound having the structure:
- 307
- or a pharmaceutically acceptable salt thereof.
A method for treating a subject having a respiratory disorder associated with the A1 adenosine receptor in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound having the structure:
- 308
- or a pharmaceutically acceptable salt thereof, so as to thereby treat the subject.
A prodrug of a compound having the structure:
- 309
- wherein the prodrug is metabolized in vivo by a human subject to an active drug which selectively inhibits the A1 adenosine receptor wherein the prodrug is
- an ester of an alcohol group;
- an acetal or ketal of an alcohol group;
- an N-Mannich base or an imine of an amine group;
- or
- a Schiff base, oxime, acetal, enol ester, oxazolidine, or thiazolidine of a carbonyl group.
A pharmaceutical composition comprising the compound having the structure:
- 310
- or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.